Valerian Root for Sleep & Insomnia

Valerian (Valeriana officinalis) is one of the most widely used herbal sleep aids in Europe, available in Irish pharmacies and health shops as a licensed herbal medicine for temporary sleep disturbance. Unlike many herbal remedies, it has attracted dozens of clinical trials. The evidence, however, is more nuanced than most marketing suggests.

Valerian's History and the Irish Context

Valerian root has been used as a sedative and anxiolytic since at least the second century AD, when the Greek physician Galen prescribed it for insomnia. In early modern Europe, valerian was one of the primary treatments for nervous conditions. In Ireland today, it is commonly available as tablets, capsules, liquid extract, and combined with other sleep herbs such as hops, lemon balm, and passionflower.

The HSE lists valerian as a herbal medicine used for sleep, and it is one of the few herbal preparations that can receive a Traditional Herbal Registration (THR) in Ireland under European regulatory frameworks, meaning it must meet standards for quality, safety, and manufacturing.

Active Compounds and Mechanisms

Valerian root contains several potentially active compounds including valerenic acid, isovaleric acid, iridoids (including valepotriates), and various flavonoids. The main proposed mechanisms are:

• GABA enhancement: Valerenic acid inhibits the GABA transaminase enzyme (which breaks down GABA) and may also act as a partial agonist at GABA-A receptors — the same receptor system targeted by benzodiazepines, though valerian's activity is far weaker and more selective
• Adenosine receptor activity: Some valerian compounds may enhance adenosine (a sleep-promoting neurotransmitter) signalling
• Serotonin receptor interaction: Valerian extracts have been shown to interact with 5-HT5a receptors, which may contribute to anxiolytic effects

Clinical Trial Evidence

The valerian evidence base is substantial in volume but inconsistent in quality and direction. A comprehensive Cochrane-style review by Fernandez-San-Martin et al. (2010) and subsequent meta-analyses have found mixed results:

Positive trials include Leathwood et al. (1982, Pharmacology Biochemistry and Behavior) finding aqueous valerian extract significantly reduced sleep latency and improved sleep quality. A 2002 trial by Donath et al. (Pharmacology Biochemistry and Behavior, n=16) found valerian improved slow-wave sleep quality in a polysomnography study. Bent et al. (2006) in the American Journal of Medicine conducted a meta-analysis of 16 studies and found valerian may improve sleep quality without side effects, though the evidence was not strong enough for definitive conclusions.

Negative or null trials also exist. A well-designed NIH-funded trial by Taibi et al. (2009) found no significant difference between valerian and placebo for sleep latency or quality in older women with insomnia. Several trials are methodologically weak (small sample sizes, subjective outcomes only, no polysomnography).

The overall picture from meta-analyses is a modest, inconsistent effect. Valerian may improve subjective sleep quality and reduce sleep onset time, but the effect size is small and not consistently replicated across all trials.

Evidence Summary

Dosing and Duration

Clinical trials have used doses of 300–600 mg of dried valerian root extract, taken 30–60 minutes before bed. Higher doses are not necessarily more effective. Standardised products (standardised to 0.8% valerenic acid) offer more consistency than non-standardised preparations.

An important and often overlooked finding from valerian trials is the delayed onset of effect. Unlike benzodiazepines, valerian may require two to four weeks of regular use before the full sleep benefit is apparent. People who try valerian for one or two nights and notice little difference may be discontinuing too early.

Safety & Interactions

Sedative medications: Valerian may potentiate the sedative effects of benzodiazepines (diazepam, lorazepam, etc.), alcohol, antihistamines, opioids, and other CNS depressants. Combining valerian with these substances could cause excessive sedation. Do not combine with prescription sleeping tablets without medical supervision.

Hepatotoxicity: Rare cases of liver damage associated with valerian supplements have been reported in the medical literature. The cases are confounded by multi-herb product use, but the possibility cannot be excluded. People with existing liver conditions should use valerian with caution and inform their GP.

Morning after effects: Some people experience morning grogginess with valerian, particularly at higher doses. Do not drive until you know how valerian affects you.

Withdrawal: After extended use of valerian, abrupt discontinuation has in rare cases been associated with a mild withdrawal-type syndrome (restlessness, tremor). Taper use rather than stopping abruptly after long-term use.

Pregnancy and breastfeeding: Valerian should not be used during pregnancy or breastfeeding due to insufficient safety data. Some valerian compounds (valepotriates) have shown cytotoxic effects in vitro.

Children: Valerian is not recommended for children under 12 years without medical supervision.

The Verdict

Valerian occupies an interesting space: it has a pharmacologically plausible mechanism, decades of clinical trial investigation, and a regulatory status as a licensed herbal medicine in Ireland. The clinical evidence is inconsistent, but a meaningful proportion of users do report improved sleep quality. The key practical advice is to give it adequate time (two to four weeks), use a standardised product at the correct dose, and be aware of the sedative interaction risks. For mild, temporary insomnia in otherwise healthy adults, valerian is a reasonable first-line herbal option. Persistent insomnia warrants GP assessment.